Enanta Pharmaceuticals (STU:9EP) Inventory Turnover: 0.00 (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Enanta Pharmaceuticals Inc STU:9EP

57 GF Score

Price €11.20

GF Value €7.54

Valuation Significantly Overvalued

6 Warning Signs

View Full Analysis

What is Enanta Pharmaceuticals Inventory Turnover?

Enanta Pharmaceuticals STU:9EP -1.75% 57 Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus rates STU:9EP with a GF Score™ of 57/100 and a GF Value™ of €7.54 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Enanta Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil. Enanta Pharmaceuticals's Average Total Inventories for the quarter that ended in Mar. 2026 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Enanta Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

Enanta Pharmaceuticals (STU:9EP) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Enanta Pharmaceuticals's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Enanta Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	0	/	14.843
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Enanta Pharmaceuticals Inventory Turnover Related Terms

Enanta Pharmaceuticals Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Inventory Turnover can be seen below:

Enanta Pharmaceuticals Inventory Turnover Chart

Enanta Pharmaceuticals Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

Inventory Turnover

Get a 7-Day Free Trial

0.00

Enanta Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

57GF Score

Enanta Pharmaceuticals Inc STU:9EP

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Enanta Pharmaceuticals Inventory Turnover Calculation

Enanta Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Sep. 2025 is calculated as

	Inventory Turnover (A: Sep. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Sep. 2025 )	/ (	(Total Inventories (A: Sep. 2024 )	+	Total Inventories (A: Sep. 2025 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Enanta Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.00 mean?

Enanta Pharmaceuticals (STU:9EP) has a Inventory Turnover of 0.00 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Enanta Pharmaceuticals and its competitors.

Is Enanta Pharmaceuticals' Inventory Turnover too high?

Enanta Pharmaceuticals' current Inventory Turnover is 0.00. Overall, Enanta Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Enanta Pharmaceuticals' Inventory Turnover compare to PBYI and IPSC?

Enanta Pharmaceuticals' Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Enanta Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €11.20 — trading 48.5% above its estimated fair value. The current Inventory Turnover is 0.00. Enanta Pharmaceuticals' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.20 is trading 48.5% above its estimated GF Value™ of €7.54. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

Inventory Turnover: 0.00
GF Value™: €7.54 vs. price of €11.20 (48.5% above fair value)
GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies PBYI IPSC BNTC FBRX LRMR AUTL XFOR CMPX SGMT PROK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges ENTA:USA 9EP:Germany

Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website https://www.enanta.com

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

57GF Score

Get the complete analysis for STU:9EP

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.20

Price

€7.54

GF Value

View STU:9EP Analysis

See Inventory Turnover data for all stocks →